Goldman Sachs’s Achilles Therapeutics ACHL Stock Holding History

Goldman Sachs’s Portfolio ACHL Stock Details ACHL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-13,247	Closed	-$30K	–	6314
2022 Q3	$30K	Sell	13,247 -82	-0.6%	-$232	﹤0.01%	5866
2022 Q2	$34K	Sell	13,329 -920	-6%	-$2.27K	﹤0.01%	6099
2022 Q1	$42K	Buy	14,249 +1,249	+10%	+$4.43K	﹤0.01%	6299
2021 Q4	$65K	Buy	+13,000	New	+$78.7K	﹤0.01%	6220

Other funds holding ACHL

Syncona Portfolio St Peter Port, Guernsey $25.7M AUM 13.32% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Goldman Sachs's ACHL Position: Q4 2022 in Review

Goldman Sachs sold out of Achilles Therapeutics (ACHL) in Q4 2022, closing a stake of 13,247 shares — an estimated $30K sold.

Goldman Sachs first reported a position in ACHL in Q4 2021 and held it in 4 quarters. The position peaked at $65K in Q4 2021. 23 funds tracked by Wall St. Rank hold ACHL as of Q4 2022.

Goldman Sachs reported no remaining Achilles Therapeutics position as of Q4 2022 after selling out during the quarter.
Goldman Sachs sold 13,247 Achilles Therapeutics shares in Q4 2022, an estimated $30K.
Goldman Sachs first reported a position in Achilles Therapeutics in Q4 2021 and held it in 4 quarters.
Goldman Sachs's Achilles Therapeutics position peaked at $65K in Q4 2021.
23 funds tracked by Wall St. Rank held Achilles Therapeutics as of Q4 2022.

Based on Goldman Sachs's 13F filing for Q4 2022, filed 13 Feb 2023.